Clinical Trial Detail

NCT ID NCT04056910
Title Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Jason J. Luke, MD
Indications

Advanced Solid Tumor

Therapies

Ivosidenib + Nivolumab

Age Groups: senior adult

Additional content available in CKB BOOST